



## Investor Webinar Presentation

- **Presentation to focus on the company's dual goals of telehealth adoption and development of a COVID-19 instant screening test**

**Brisbane, Australia, 18 August 2021** – ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease is pleased to announce its participation in the ShareCafe Small Cap “Hidden Gems” Webinar, to be held on Friday 20 August 2021 at 12:30pm AEST / 10:30am AWST.

Brian Leedman, Co-Founder and Executive Director, Corporate Affairs, will provide an update on the company's recent achievements with particular focus on the dual goals of telehealth adoption and development of a COVID-19 instant screening test.

To access further details of the event and to register at no cost, please follow the link below:

[https://us02web.zoom.us/webinar/register/5416151767246/WN\\_8mZL8zwVSaqS1IuuVcTmtw](https://us02web.zoom.us/webinar/register/5416151767246/WN_8mZL8zwVSaqS1IuuVcTmtw)

A copy of the webinar will be made available following the event and a copy of the investor presentation to be delivered during the webinar is attached.

### **About ResApp Health Limited**

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit [www.resapphealth.com.au](http://www.resapphealth.com.au).

### **Contacts**

Dr Tony Keating  
CEO and Managing Director  
+61 430 180 659  
[tony@resapphealth.com.au](mailto:tony@resapphealth.com.au)

Mr Brian Leedman  
Executive Director, Corporate Affairs  
+61 412 281 780  
[brian@resapphealth.com.au](mailto:brian@resapphealth.com.au)

*This ASX announcement was approved and authorised for release by the board of directors of ResApp Health.*